Join in-person or online for the ImmUnity Canada National Conference on April 14–16, 2023 — Click here for more information.

Q

Advocacy

ImmUnity Canada advocates for all Canadians with immunodeficiency disorders to have access to the resources they need to thrive. 

The Key Issues Affecting the Immunity Canada Community

Advocacy is an important part of ImmUnity Canada’s mission and ongoing work. We actively consult with medical professionals, members and the community to advocate for primary immunodeficiency causes at the provincial and federal levels.

Contact us for more information on our current causes and campaigns and to learn how you can get involved and support these issues.

Newborn Screening

SCID

Newborn Screening for SCID is vital in the early detection of this rare and severe form of primary immunodeficiency. Without newborn screening, infants have a less than 40% survival rate, and with newborn screening, that number is more than 90%. Currently, newborn screening for SCID is approved in all provinces and territories except Newfoundland.

ImmUnity Canada has a vital role to play as the patient voice makes a difference in these applications. In 2020, ImmUnity Canada began working with immunologists and BC families to advocate for the inclusion of SCID testing on the existing BC newborn screening panel. Starting October 1, 2022, all babies born in British Columbia and the Yukon are now screened for SCID.

Federal Newborn Screening Program

Immunity Canada has partnered with the Network for Rare Blood Disorders (NRBDO) on a joint initiative to evaluate the possibility of a federal newborn screening program. The resulting report, “Timing is Everything: towards a federal newborn screening program,” will be available in January 2023.

Comprehensive Care

Comprehensive care is one of ImmUnity Canada’s core causes and programs, working to ensure that all primary immunodeficiency patients have access to the best care possible.

Our Comprehensive Care Goals

  • Dedicated clinics nationwide
  • Each clinic has a dedicated nurse
  • Access to specialists with knowledge of primary immunodeficiency (gastrointestinal, rheumatology, etc.)
  • Access to a social worker
  • A program to aid the transition from pediatric to adult care
  • Patient Registration

ImmUnity Canada aims for the creation of at least one Dedicated Centre for Primary Immunodeficiency in each province.

Read the IPOPI Principles of Care Implementation Package.

Product and Supply Accessibility

No patient should worry about where their product or supplies are coming from. No patient should worry about being able to afford their supplies or product. No patient should worry about whether their hospital or blood bank will carry their product. ImmUnity Canada is dedicated to advocating to ensure that this will not happen.

Awareness and Early Diagnosis

Primary Immunodeficiency diseases are rare. Currently, the standard time to diagnosis in  Canada is 6-12 years. An estimated 80% of patients are undiagnosed in Canada, and over 5,000 new patients are diagnosed each year. Through education and raising awareness of PI, we can help get more patients diagnosed earlier.

PI and Emergency Medicine

ImmUnity Canada aims to improve the PI patient and caregiver experience with emergency medicine. In 2020, ImmUnity Canada partnered with the National Emergency Nurses Association (NENA) on a program that provides PI patients with wallet cards, as well as the development of emergency room guidelines for PI.

MSM Donation Deferral

In 2019, Canadian Blood Services announced plans to move to a behaviour-based donation questionnaire in an effort to remove the current 3-month time deferral on men who have sex with men (known as MSM in blood collection).  Canadian Blood Services submitted to Health Canada in 2020 a pilot to include MSM donors in plasma collection. ImmUnity Canada (then the Canadian Immunodeficiencies Patient Organization) supported this application, along with other organizations (including the NRBDO, GBS/CIDP Foundation of Canada and others). As representatives of a plasma-user community, we believe that there is no increased risk to plasma protein products with the inclusion of MSM donors, given the safety measures in place, such as viral inactivation and testing.

Read our letter to the Health Minister: Letter of Support to MSM (2021)

Drug and Medication Shortages

The COVID-19 pandemic and global supply chain disruptions may result in medication and drug shortages. Visit the website below to check the status of your prescribed medications.

Immunoglobulin Supply – IVIG Shortages

Due to global supply issues, Canada is experiencing intermittent IVIG shortages. Currently, patients using IVIG can expect to experience changes in vial sizes and changes in product brand. Some patients may be evaluated and asked to switch to a different method of treatment, SCIG.

Please contact your prescribing physician or email info@immunitycanada.org if you have any concerns.

Join our newsletter

Get news, information and event updates from ImmUnity Canada.


By submitting this form, you are consenting to receive marketing emails from: ImmUnity Canada, 206-645 Fort Street, Victoria, BC, V8W1G2, https://immunitycanada.org/. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact